

SIROS™

Control your Y-90 delivery with confidence



Advancing to the next level.

SIROS is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.



Visual

- Visually controlled administration enables precision



Intuitive

- Intuitive design for easy set-up, fluid administration and quick disposal



Versatile


- Enhanced control allows for more options to tailor sphere delivery



*Y-90 resin microspheres

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. SIR-Spheres Y-90 resin microspheres may only be distributed to a duly licensed or accredited facility capable of handling therapeutic medical isotopes. This product is radioactive and should thus be handled in accordance with all applicable standards and regulations.

Indications For Use: In the US, SIR-Spheres Y-90 resin microspheres have a Pre-Market Approval (PMA) from the FDA and are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). **Warnings / Precautions:** Inadvertent delivery of the microspheres to locations other than the intended hepatic tumor may result in local radiation damage. Due to the radioactivity and the significant consequences of misplacing the microspheres in situ, this product must be implanted by physicians who have completed the Sirtex TEC training program. A SPECT scan of the upper abdomen immediately after implantation is recommended. Patients may experience abdominal pain immediately after administration and pain relief may be required. H-2 blocking agents may be administered the day before implantation and continued as needed to reduce gastric complications. **Side Effects:** Common side effects are fever, transient decrease of hemoglobin, mild to moderate abnormality of liver function tests, abdominal pain, nausea, vomiting, and diarrhea. Potential serious effects due to exposure to high radiation include acute pancreatitis, radiation pneumonitis, acute gastritis, radiation hepatitis, and acute cholecystitis. **Contraindications:** SIR-Spheres Y-90 resin microspheres should not be implanted in patients who have either had previous external beam radiation therapy to the liver, ascites, or are in clinical liver failure. This device is contraindicated in patients with markedly abnormal synthetic and excretory liver function tests, greater than 20% lung shunting of the hepatic artery blood flow, disseminated extra-hepatic malignant disease, and portal vein thrombosis. This device should not be implanted in patients determined via angiogram to have an abnormal vascular anatomy that would result in significant reflux of the hepatic arterial blood flow to the stomach, pancreas or bowel. **Reference the Instructions for Use (www.sirtex.com) for a complete listing of indications, contraindications, side effects, warnings, and precautions.**

 **Manufacturer**
Sirtex Medical Pty Ltd Shop 6, 207 Pacific Highway St Leonards, NSW 2065 Australia Tel: +61 2 9964 8400 Fax: +61 2 9964 8410
Americas Sirtex Medical Inc. 300 Unicorn Park Drive Woburn, MA 01801 USA Tel: +1 888 474 7839

www.sirtex.com  @SirtexMedical  company/sirtex-medical-limited  @SIRSpheresmicrospheres  @SirtexMedicalUS

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. ©2021 Sirtex Medical Inc. APM-US-033-07-20 V2

SIRTeX